Confirmed Control Closed Deal verified ConsumerConsumer HealthConsumer Health / OTC PharmaceuticalsOTC MedicinesPharmaceutical Manufacturing

Viatris OTC business acquired by Cooper Consumer Health

Cooper Consumer Health acquired Viatris OTC business, an Europe consumer health / otc pharmaceuticals brand on Oct 1, 2023. FundComb records estimated consideration of USD 2. The current comp implies EV / revenue of 3.6x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.

Transaction summary

Target
Viatris OTC business
Acquirer
Cooper Consumer Health
Seller
Viatris
Announced
2023-10-01
Geography
Europe
Tags
ConsumerConsumer HealthConsumer Health / OTC PharmaceuticalsOTC MedicinesPharmaceutical Manufacturing
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-06-19
Latest update
2026-06-19

Value and multiples

Price / value

$2

Unknown | USD

Basis: FundComb estimate

EV / revenue

3.6x

unknown

Basis: FundComb estimate

EV / EBITDA

12.8x

Basis: FundComb estimate

Basis

  • USD 2 unknown is a FundComb estimate. Public sources reviewed confirm the transaction, but do not independently disclose every valuation input.
  • EV / revenue is shown as 3.6x based on the available comp inputs.
  • Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
  • EV / EBITDA is shown as 12.8x based on the available comp inputs.

Source summary

No public source summary has been published for this transaction yet.